Literature DB >> 8380058

p53 mutations and aflatoxin B1 exposure in hepatocellular carcinoma patients from Thailand.

M C Hollstein1, C P Wild, F Bleicher, S Chutimataewin, C C Harris, P Srivatanakul, R Montesano.   

Abstract

The prevalence and type of mutations in the p53 tumour-suppressor gene have been determined in 15 hepatocellular carcinomas (HCC) originating from Thailand. Direct sequencing of exons 5-8 revealed 2 mutations, an AGG to AGT (Arg-->Ser) transversion at codon 249, and an ATC-->AAC (Ile-->Asn) transversion at codon 254. Samples from the Thai patients were analyzed for the presence of aflatoxin-liver DNA and aflatoxin-serum albumin adducts, and all but one were found negative. All the patients were genotyped for glutathione-S-transferase (GST) mu, an enzyme possibly involved in the detoxification of AFB1, and 12 out of 15 had the null genotype. In general, the level of aflatoxin-albumin adducts in sera and the prevalence of p53 mutation at codon 249 in HCC were lower than in other areas at high risk of HCC, including southern China and parts of Africa.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8380058     DOI: 10.1002/ijc.2910530111

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  15 in total

Review 1.  Soft tissue sarcomas and p53 mutations.

Authors:  H Taubert; A Meye; P Würl
Journal:  Mol Med       Date:  1998-06       Impact factor: 6.354

2.  Susceptibility to hepatocellular carcinoma associated with null genotypes of GSTM1 and GSTT1.

Authors:  Jian-Chao Bian; Fu-Ming Shen; Li Shen; Tian-Ru Wang; Xiao-Hong Wang; Gong-Chao Chen; Jin-Bing Wang
Journal:  World J Gastroenterol       Date:  2000-04       Impact factor: 5.742

3.  Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma.

Authors:  Nishant Agrawal; Yuchen Jiao; Chetan Bettegowda; Susan M Hutfless; Yuxuan Wang; Stefan David; Yulan Cheng; William S Twaddell; Nyan L Latt; Eun J Shin; Li-Dong Wang; Liang Wang; Wancai Yang; Victor E Velculescu; Bert Vogelstein; Nickolas Papadopoulos; Kenneth W Kinzler; Stephen J Meltzer
Journal:  Cancer Discov       Date:  2012-08-09       Impact factor: 39.397

4.  Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma.

Authors:  Bin Yang; Mingzhou Guo; James G Herman; Douglas P Clark
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

5.  Preventive effect of Metformin against N-nitrosodiethylamine-initiated hepatocellular carcinoma in rats.

Authors:  Muhammad Afzal; Imran Kazmi; Gaurav Gupta; Mahfoozur Rahman; Vishwadeepak Kimothi; Firoz Anwar
Journal:  Saudi Pharm J       Date:  2012-06-09       Impact factor: 4.330

6.  Immunohistochemical analysis of p53 protein overexpression in liver cell dysplasia and in hepatocellular carcinoma.

Authors:  M Zhao; N X Zhang; J A Laissue; A Zimmermann
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

Review 7.  Indoor mold, toxigenic fungi, and Stachybotrys chartarum: infectious disease perspective.

Authors:  D M Kuhn; M A Ghannoum
Journal:  Clin Microbiol Rev       Date:  2003-01       Impact factor: 26.132

8.  Is p53 gene mutation an indicatior of the biological behaviors of recurrence of hepatocellular carcinoma?

Authors:  I-Shyan Sheen; Kuo-Shyang Jeng; Ju-Yann Wu
Journal:  World J Gastroenterol       Date:  2003-06       Impact factor: 5.742

9.  Tumor metabolism and associated serum metabolites define prognostic subtypes of Asian hepatocellular carcinoma.

Authors:  Yotsawat Pomyen; Anuradha Budhu; Jittiporn Chaisaingmongkol; Marshonna Forgues; Hien Dang; Mathuros Ruchirawat; Chulabhorn Mahidol; Xin Wei Wang
Journal:  Sci Rep       Date:  2021-06-08       Impact factor: 4.996

10.  Epigenetic influences in the aetiology of cancers arising from breast and prostate: a hypothesised transgenerational evolution in chromatin accessibility.

Authors:  Francis L Martin
Journal:  ISRN Oncol       Date:  2013-02-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.